Vicore and Nippon Shinyaku sign agreement to commercialize C21 in Japan 12-Feb-2024 By Isabel Cameron Vicore Pharma has entered into an exclusive licensing agreement with Japanese pharmaceutical company Nippon Shinyaku to commercialize Vicore’s idiopathic pulmonary fibrosis (IPF) drug candidate C21 in Japan.